Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor
NEW YORK and LONDON and MUNICH and NEW DELHI, Feb. 11, 2025…
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) --…
CERE Partners with BNP Paribas to Solarise ACTREC, Driving Sustainable Cancer Research
MUMBAI, India, Feb. 5, 2025 /PRNewswire/ -- On the occasion of World Cancer…
Patient Advocates from NCCN Guidelines Panels Share Their ‘United by Unique’ Stories for World Cancer Day
The National Comprehensive Cancer Network joins a global day of advocacy to…
Growing Incidence of Cancer is Denting the ‘Viksit Bharat 2047’ Vision – Global Sustainability Alliance Experts
Cancer cases in India will see a 57.7% increase by 2040, unless…
Datar Cancer Genetics Unveils Next Generation Multi-Analyte, AI-Powered Decision Support Platform for Personalized Treatment of Difficult-to-Treat Cancers.
LONDON, MUNICH and NEW DELHI, Feb. 3, 2025 /PRNewswire/ -- Datar Cancer Genetics…
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor…
Datar Cancer Genetics to Provide Groundbreaking Video-Enhanced Results of In-Vitro Chemotherapy Effectiveness Tests for Cancer Patients
NEW DELHI and LONDON and MUNICH, Jan. 28, 2025 /PRNewswire/ -- Datar…
Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…